Valuation: Spero Therapeutics, Inc.

Market Cap 73.38M 64.4M 60.54M 55.35M 103M 7.03B 104M 727M 282M 3.58B 276M 270M 11.62B P/E 2026 *
-2.17x
P/E 2027 * -12x
Enterprise Value 73.38M 64.4M 60.54M 55.35M 103M 7.03B 104M 727M 282M 3.58B 276M 270M 11.62B EV / Sales 2026 *
284x
EV / Sales 2027 * -
Free-Float
77.39%
Yield 2026 *
-
Yield 2027 * -
1 day-7.35%
1 week+13.51%
Current month+3.28%
1 month+3.28%
3 months-41.40%
6 months-46.38%
Current year-45.92%
1 week 1.12
Extreme 1.115
1.44
1 month 1.1
Extreme 1.1
1.44
Current year 1.08
Extreme 1.08
3.08
1 year 1.08
Extreme 1.08
3.08
3 years 0.51
Extreme 0.5052
3.22
5 years 0.51
Extreme 0.5052
19.87
10 years 0.51
Extreme 0.5052
23.64
Manager TitleAgeSince
Chief Executive Officer 47 10/01/2025
Chief Tech/Sci/R&D Officer 69 27/07/2026
Chief Operating Officer 58 01/02/2023
Director TitleAgeSince
Chairman 69 01/01/2014
Director/Board Member 62 01/09/2015
Chairman 56 10/01/2025
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 A Free

Chief Technology Officer

486,986 0.8411%
5/4/26 A Sell

Chief Executive Officer

-25,240 0.0436%
2/6/26 A Sell

Chief Executive Officer

87,917 0.1560%
Change 5-day change 1-year change 3-year change Capi.($)
-7.35%+13.51%-37.31%+4.13% 73.38M
+0.06%+6.49%+60.29%+111.13% 74.18B
+0.22%-3.50%+34.66%+75.52% 59.55B
-2.05%-3.46%-18.60%+352.20% 25.84B
-2.39%+2.74%+0.19%-5.91% 24.73B
-0.87%+1.25%+21.66%-9.88% 20.87B
+1.29%-2.49%+152.11%+333.06% 15.32B
-2.44%-0.09%+42.50%+164.11% 14.06B
-3.91%-4.91%-14.10%+779.68% 13.12B
-1.12%-3.04%+15.72%+234.56% 11.85B
Average -1.86%+0.99%+25.71%+203.86% 25.96B
Weighted average by Cap. -0.74%+0.71%+36.36%+161.45%

Financials

2026 *2027 *
Net sales 258K 226K 213K 195K 364K 24.71M 366K 2.56M 991K 12.6M 969K 948K 40.85M -
Net income -33.46M -29.36M -27.6M -25.24M -47.16M -3.2B -47.51M -332M -129M -1.63B -126M -123M -5.3B -51.5M -45.2M -42.49M -38.85M -72.59M -4.93B -73.13M -510M -198M -2.52B -193M -189M -8.15B
Net Debt - -
Logo Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Employees
25
Date Price Change Volume
23/09/26 $1.260 -7.35% 1,403,213
22/09/26 $1.360 +19.30% 7,764,493
21/09/26 $1.140 +0.88% 319,103
18/09/26 $1.130 +0.89% 501,371
17/09/26 $1.120 +0.90% 181,774
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.260USD
Average target price
5.000USD
Spread / Average Target
+296.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRO Stock